home / stock / acer / acer news


ACER News and Press, Acer Therapeutics Inc. From 03/22/23

Stock Information

Company Name: Acer Therapeutics Inc.
Stock Symbol: ACER
Market: NASDAQ
Website: acertx.com

Menu

ACER ACER Quote ACER Short ACER News ACER Articles ACER Message Board
Get ACER Alerts

News, Short Squeeze, Breakout and More Instantly...

ACER - Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today...

ACER - Enzo, PaxMedica top healthcare gainers; Lifecore, Acer lead losers' pack

2023-03-17 10:02:41 ET Gainers: Enzo Biochem ( ENZ ) +77% . PaxMedica ( PXMD ) +22% . Nuwellis (NUWE ) +18% . Lucy Scientific Discovery ( LSDI ) +12% . Assure Holdings ( IONM ) +8% . Losers: Lifecore Biomedical (...

ACER - Acer stock slumps ~45% as ACER-801 paused after hot flashes trial disappoints; cash woes

2023-03-17 09:16:37 ET Acer Therapeutics ( NASDAQ: ACER ) is pausing a program for its drug ACER-801 (osanetant) after the medicine failed to meet the efficacy goals of a phase 2a trial to treat hot flashes in postmenopausal women. The proof of concept trial w...

ACER - Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

NEWTON, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today...

ACER - Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA(TM) Program Update

Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders (UCDs) OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023...

ACER - 7 Penny Stocks With Strong Insider Buying Signals

2023-03-05 12:10:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to penny stocks , a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be st...

ACER - Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced full en...

ACER - 7 Micro-Cap Stocks to Buy for Risk-Taking Investors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now’s a great time to start considering which micro-cap stocks to buy. Generally, micro-caps are stocks with a market capitalization of less than $300 million. With a cap like that, the company doesn’t have a to...

ACER - Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

NEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases w...

ACER - Acer Therapeutics rises on starting trial of ACER-801 in men with adenocarcinoma of the prostate

Acer Therapeutics ( NASDAQ: ACER ) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate. The two-trials are - The POSH-MAP, which is Pilot of Osanetant for Severi...

Previous 10 Next 10